Envestnet Asset Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
Envestnet Asset Management's BEAM Position: Q1 2026 in Review
Envestnet Asset Management increased its Beam Therapeutics (BEAM) stake by 34% in Q1 2026, buying an estimated $296K and bringing the position to 42,194 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3470.
Envestnet Asset Management first reported a position in BEAM in Q3 2021 and has held it in 17 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- Envestnet Asset Management held 42,194 shares of Beam Therapeutics worth $1.01M as of Q1 2026.
- Envestnet Asset Management bought 10,662 Beam Therapeutics shares in Q1 2026, an estimated $296K.
- Beam Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #3470 holding.
- Envestnet Asset Management first reported a position in Beam Therapeutics in Q3 2021 and has held it in 17 quarters since.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.